Edurant Ped

Generic name: rilpivirine

Used for: HIV

How do you pay?

How to pay the least

Ask for the cash price

Edurant Ped

We didn’t find one.

  1. Ask your pharmacy for Edurant Ped’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameEdurant Ped
Authorized genericrilpivirine
Regular genericrilpivirine
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Edurant Ped?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Edurant Ped’s maker. Ask the pharmacy for Edurant Ped’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Edurant Ped itself, from the same company, sold without the brand name, and usually for less. For now Edurant Ped is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Edurant Ped’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

EDURANT and EDURANT PED are a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 2 years of age and older and weighing at least 14 kg with HIV-1 RNA less than or equal to 100,000 copies/mL..

Limitations of Use:

  • More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to EDURANT treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL.

EDURANT is indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Source: the FDA label for Edurant Ped (Janssen Products, LP), August 28, 2025. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/edurant-ped/